Peel Hunt reiterated their buy rating on shares of PureTech Health (LON:PRTC) in a report issued on Monday, Stock Target Advisor reports.
Several other brokerages also recently commented on PRTC. Peel Hunt restated a buy rating and issued a GBX 380 ($4.97) price target on shares of PureTech Health in a research report on Wednesday, October 2nd. Liberum Capital restated a buy rating and issued a GBX 300 ($3.92) price target (down previously from GBX 347 ($4.53)) on shares of PureTech Health in a research report on Friday.
Shares of LON:PRTC traded up GBX 41 ($0.54) during mid-day trading on Monday, hitting GBX 290 ($3.79). The stock had a trading volume of 1,607,659 shares, compared to its average volume of 71,917. The company has a debt-to-equity ratio of 31.14, a quick ratio of 0.67 and a current ratio of 0.69. The company has a market cap of $827.26 million and a PE ratio of -103.57. PureTech Health has a 12-month low of GBX 155.50 ($2.03) and a 12-month high of GBX 307 ($4.01). The company’s 50 day moving average is GBX 245.80 and its 200-day moving average is GBX 245.38.
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Read More: Why do earnings reports matter?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.